| HNSA Stock | | | SEK 31.00 0.50 1.59% |
CFO
Mr.Donato Spota will be appointing as a Chief Financial Officer of the company, Effective May 15, 2019 since 2019.
| Age | 52 |
| Tenure | 5 years |
| Phone | 46 46 16 56 70 |
| Web | https://www.hansabiopharma.com |
Spota is a senior executive with more than 20 years of international pharmaceutical industry experience, including strategic finance, investor relations and international capital markets transactions. Prior to joining Hansa, Mr. Spota was with Basilea Pharmaceutica AG, a Swiss listed biopharmaceutical company, for 16 years where he served as CFO for the past five years.
Hansa Biopharma Management Efficiency
The company has return on total asset
(ROA) of
(0.2718) % which means that it has lost $0.2718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.8941) %, meaning that it generated substantial loss on money invested by shareholders. Hansa Biopharma's management efficiency ratios could be used to measure how well Hansa Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Hansa Biopharma AB has accumulated 783.93
M in total debt with debt to equity ratio
(D/E) of 1.6, which is about average as compared to similar companies. Hansa Biopharma AB has a current ratio of 15.14, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hansa Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Hansa Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hansa Biopharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hansa to invest in growth at high rates of return. When we think about Hansa Biopharma's use of debt, we should always consider it together with cash and equity.
Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people. Hansa Biopharma AB (HNSA) is traded on Stockholm Exchange in Sweden and employs 150 people.
Management Performance
Hansa Biopharma AB Leadership Team
Elected by the shareholders, the Hansa Biopharma's board of directors comprises two types of representatives: Hansa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hansa. The board's role is to monitor Hansa Biopharma's management team and ensure that shareholders' interests are well served. Hansa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hansa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henk Troostwijk, Vice President Commercial Operations | |
| Klaus Sindahl, Head Relations | |
| Sren MSc, Pres CEO | |
| Donato Spota, CFO VP | |
| Christian Kjellman, Senior Vice President Research and Development | |
| Lena Winstedt, Vice President Project Management | |
| Katja Margell, Head Communications | |
| EvaMaria Joed, Vice President Finance & Administration | |
| Anne Lanner, VP Officer | |
| Emanuel Bjrne, VP Devel | |
Hansa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hansa Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to
measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to
predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.